Robert Funsten is Counsel in the Firm’s Corporate Practice Group. Prior to becoming Counsel, Rob was a partner at the Firm and Co-Chair of the Firm’s Global Life Sciences Group. Rob’s transactional, M&A, and securities practice focuses on advising life sciences companies, including pharmaceutical, medical device, diagnostic, biotechnology, biopharmaceutical, biomedical, nutraceutical, and other healthcare industry firms.
Rob is a seasoned life sciences industry professional. He has extensive experience advising life sciences companies, from emerging growth companies and startups to large multinational public companies, in licensing and development deals, intellectual property and technology transfer agreements, strategic alliances, collaborations and joint ventures, mergers and acquisitions, supply, distribution, marketing and promotion arrangements, debt and equity financings, and other business transactions.
Prior to joining Brown Rudnick, Rob was the Co-Chair of the Life Sciences Practice of a global AmLaw 100 firm. Before that, Rob was Senior Vice President, General Counsel, and Corporate Secretary of Watson Pharmaceuticals (now Actavis Group), a multibillion-dollar specialty pharmaceutical company. Rob also served as the Vice President, General Counsel of Chiron Vision Corporation (now a part of Bausch & Lomb), an ophthalmic medical device company, and as Corporate Secretary of ISTA Pharmaceuticals, a branded pharmaceutical company (now a part of Bausch & Lomb).
Awards
Representation
Represented pharmaceutical company in connection with its acquisition of a late-stage, privately held women’s health biopharmaceutical company.
Represented transnational pharmaceutical company in connection with its $880 million acquisition of a privately-held pharmaceutical company.
Represented pharmaceutical company in connection with a cross-border strategic licensing and development agreement.
Represented publicly traded medical device company in connection with a structured investment in, and an option to acquire, a privately-held medical technology company.
Represented investigational-stage pharmaceutical company in connection with its Series A financing.
Represented lead investor in formation of joint venture for acquisition of brand drug out of bankruptcy.
Represented publicly-traded medical device company in connection with its participation as lead investor in a $50 million financing of a venture-backed private company developing a catheter-based treatment for heart failure and the grant to the public company of an option to acquire the private company based on future regulatory milestones.
Represented pharmaceutical company in connection with a joint development agreement to apply proprietary technologies to multiple therapeutic compounds.
Represented medical device company in connection with a collaboration agreement for the development and commercialization of glucose monitoring systems.
Represented generic pharmaceutical company in its settlement of Hatch-Waxman patent litigation, including negotiation of a license agreement allowing for sale of the generic version of the brand drug prior to expiration of the brand company’s patent.
Represented pharmaceutical manufacturer in connection with its acquisition of U.S. and European manufacturing facilities and certain product-lines.
Represented publicly held biotechnology company in its merger with a privately held life sciences company.
Represented medical device company in connection with an exclusive license agreement related to certain cardiovascular technologies.
Represented various life sciences companies in connection with exclusive licensing arrangements with major Universities.
Represented pharmaceutical company in connection with an exclusive license agreement concerning a novel compound to be developed for certain therapeutic applications.
Represented medical device company in connection with the divestiture of certain product lines.
Represented pharmaceutical company in connection with a development and license agreement related to a novel hormone replacement product.
Represented pharmaceutical company in connection with the formation of a joint venture to commercialize FDA approved drug product.
Represented pharmaceutical company in connection with its acquisition of marketing rights and a distribution and supply agreement of a pharmaceutical product.
Represented medical device company in connection with a distribution arrangement for an ophthalmic medical device.
Represented pharmaceutical company in connection with a co-promotion agreement of a brand pharmaceutical product.
Represented medical device company in connection with its investment in development stage company and technology evaluation agreement.
Represented pharmaceutical company in connection with various public offerings of its common stock and convertible debt.
Represented underwriters in connection with IPO of developer and manufacturer of wound care products.
Represented pharmaceutical developer in connection with a private offering of its common stock to venture capital investors.
Represented pharmaceutical, medical device, and other life sciences companies in connection with acquisitions of various companies and businesses.
Represented pharmaceutical, medical device, and other life science companies in connection with development, supply, distribution, and various other commercial agreements.
Education
Bar Admissions
| Publications |
| Speaking Engagements |
| Professional Affiliations |
| Awards and Honors |
© 2021 Brown Rudnick LLP. Attorney Advertising